Nonalcoholic fatty liver disease and cholesterol gallstones: Which comes first?

Scandinavian Journal of Gastroenterology

Volumn 49, Issue 5, 2014, Pages 521-527

  Ahmed, Mohamed H ^a   Ali, Asif ^a  

^a MILTON KEYNES UNIVERSITY HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Cholesterol gallstones; Fatty liver; Insulin resistance; Obesity and metabolic syndrome

Indexed keywords

CHOLESTEROL; FIBRIC ACID DERIVATIVE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN; PRAVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL; URIC ACID; URSODEOXYCHOLIC ACID;

BODY MASS; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL STONE; CROSS-SECTIONAL STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; DYSLIPIDEMIA; GALLSTONE FORMATION; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN RESISTANCE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; PATHOGENESIS; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; URIC ACID BLOOD LEVEL; WAIST CIRCUMFERENCE; CHEMISTRY; COMPLICATION; DYSLIPIDEMIAS; GALLSTONE;

CHOLESTEROL; DYSLIPIDEMIAS; GALLSTONES; HUMANS; INSULIN RESISTANCE; METABOLIC SYNDROME X; NON-ALCOHOLIC FATTY LIVER DISEASE; OBESITY; RISK FACTORS;

EID: 84899005488     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.3109/00365521.2014.894119     Document Type: Review

References (61)

1. Sandler RS, Everhart JE, Donowitz M, et al. The burden of selected digestive diseases in the United States. Gastroenterology 2002;122:1500-11. (Pubitemid 34465190
2. Shaffer EA. Epidemiology and risk factors for gallstone disease: Has the paradigm changed in the 21st century?. Curr Gastroenterol Rep 2005;7:132-40
3. Marschall HU, Einarsson C. Gallstone disease. J Intern Med 2007;261:529-42. (Pubitemid 46835981
4. Shaffer EA. Gallstone disease: Epidemiology of gallbladder stone disease. Best Pract Res Clin Gastroenterol 2006;20: 981-96. (Pubitemid 44793722
5. Ahmed MH, Hamad MA, Routh C, Connolly V. Statins as potential treatment for cholesterol gallstones: An attempt to understand the underlying mechanism of actions. Expert Opin Pharmacother 2011;12:2673-81
6. Wang HH, Portincasa P, Wang DQ. Molecular pathophysiology and physical chemistry of cholesterol gallstones. Front Biosci 2008;13:401-23. (Pubitemid 351599753
7. Wang HH, Portincasa P, Afdhal NH, Wang DQ. Lith genes and genetic analysis of cholesterol gallstone formation. Gastroenterol Clin North Am 2010;39:185-207; vii-viii
8. Nakagawa S, Makino I, Ishizaki T, Dohi I. Dissolution of cholesterol gallstones by ursodeoxycholic acid. Lancet 1977; 2:367-9. (Pubitemid 8164394
9. Petroni ML, Jazrawi RP, Pazzi P, et al. Risk factors for the development of gallstone recurrence following medical dissolution. The British-Italian Gallstone Study Group. Eur J Gastroenterol Hepatol 2000;12:695-700. (Pubitemid 30433548
10. Muhidin SO, Magan AA, Osman KA, Syed S, Ahmed MH. The relationship between nonalcoholic fatty liver disease and colorectal cancer: The future challenges and outcomes of the metabolic syndrome. J Obes 2012;2012:637538
11. Ahmed MH, Byrne CD. Non-Alcoholic fatty Liver disease. In Byrne C, Wild S, editors. The Metabolic syndrome. Wiley-Blackwell; 2011. pp 245-77
12. Ahmed MH, Byrne CD. Non alcoholic steatatohepatitis and metabolic syndrome. In Byrne C, Wild S, Metabolic syndrome. Chichester, UK: John Wiley & Sons; 2005. pp 279-305
13. Dixon JB, Bhathal PS, O'Brien PE. Nonalcoholic fatty liver disease: Predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 2001; 121:91-100. (Pubitemid 32591518
14. Byrne CD, Olufadi R, Bruce KD, Cagampang FR, Ahmed MH. Metabolic disturbances in non-Alcoholic fatty liver disease. Clin Sci (Lond) 2009;116:539-64
15. Jimba S, Nakagami T, Takahashi M, et al. Prevalence of nonalcoholic fatty liver disease and its association with impaired glucose metabolism in Japanese adults. Diabet Med 2005;22: 1141-5. (Pubitemid 41224170
16. Adams LA, Lymp JF, St SJ, et al. The natural history of nonalcoholic fatty liver disease: A population-based cohort study. Gastroenterology 2005;129:113-21. (Pubitemid 41002048
17. Adams LA, Harmsen S, St Sauver JL, et al. Nonalcoholic fatty liver disease increases risk of death among patients with diabetes: A community-based cohort study. Am J Gastroenterol 2010;105:1567-73
18. Schwimmer JB, Deutsch R, Kahen T, Lavine JE, Stanley C, Behling C. Prevalence of fatty liver in children and adolescents. Pediatrics 2006;118:1388-93. (Pubitemid 46393782
19. Ahmed MH. Biochemical markers: The road map for the diagnosis of nonalcoholic fatty liver disease. Am J Clin Pathol 2007;127:20-2. (Pubitemid 46797013
20. Ruhl CE, Everhart JE. Gallstone disease is associated with increased mortality in the United States. Gastroenterology 2011;140:508-16
21. Mendez-Sanchez N, Bahena-Aponte J, Chavez-Tapia NC, et al. Strong association between gallstones and cardiovascular disease. Am J Gastroenterol 2005;100:827-30. (Pubitemid 40592374
22. Mendez-Sanchez N, Zamora-Valdes D, Flores-Rangel JA, et al. Gallstones are associated with carotid atherosclerosis. Liver Int 2008;28:402-6
23. Ahmed MH, Barakat S, Almobarak AO. Nonalcoholic fatty liver disease and cardiovascular disease: Has the time come for cardiologists to be hepatologists?. J Obes 2012;2012: 483135
24. Koller T, Kollerova J, Hlavaty T, Huorka M, Payer J. Cholelithiasis and markers of nonalcoholic fatty liver disease in patients with metabolic risk factors. Scand J Gastroenterol 2012;47:197-203
25. Ruhl CE, Everhart JE. Relationship of non-Alcoholic fatty liver disease with cholecystectomy in the US population. Am J Gastroenterol 2013;108:952-8
26. Loria P, Lonardo A, Lombardini S, et al. Gallstone disease in non-Alcoholic fatty liver: Prevalence and associated factors. J Gastroenterol Hepatol 2005;20:1176-84. (Pubitemid 41602559
27. Fracanzani AL, Valenti L, Russello M, et al. Gallstone disease is associated with more severe liver damage in patients with non-Alcoholic fatty liver disease. PLoS One 2012;7:e41183
28. Yener O, Aksoy F, Demir M, Ozcelik A, Erengul C. Gallstones associated with nonalcoholic steatohepatitis (NASH) and metabolic syndrome. Turk J Gastroenterol 2010;21:411-15
29. Fraenkel E, Takacs R, Hamvas J, Lengyel G, Feher J. [Common occurrence of non-Alcoholic fatty liver disease and cholecystolithiasis]. Orv Hetil 2007;148:793-8
30. Lonardo A, Lombardini S, Scaglioni F, et al. Fatty liver, carotid disease and gallstones: A study of age-related associations. World J Gastroenterol 2006;12:5826-33. (Pubitemid 44594251
31. Ahmed MH, Byrne CD. Current treatment of non-Alcoholic fatty liver disease. Diabetes Obes Metab 2009;11:188-95
32. Bellentani S, Saccoccio G, Masutti F, et al. Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med 2000;132:112-17. (Pubitemid 30044177
33. Rocha R, Cotrim HP, Carvalho FM, Siqueira AC, Braga H, Freitas LA. Body mass index and waist circumference in nonalcoholic fatty liver disease. JHumNutr Diet 2005;18:365-70. (Pubitemid 41387905
34. Chen LY, Qiao QH, Zhang SC, Chen YH, Chao GQ, Fang LZ. Metabolic syndrome and gallstone disease. World J Gastroenterol 2012;18:4215-20
35. Tsai CJ, Leitzmann MF, Willett WC, Giovannucci EL. Prospective study of abdominal adiposity and gallstone disease in US men. Am J Clin Nutr 2004;80:38-44. (Pubitemid 41115552
36. Kim SS, Lee JG, Kim DW, et al. Insulin resistance as a risk factor for gallbladder stone formation in Korean postmenopausal women. Korean J Intern Med 2011;26:285-93
37. Shebl FM, Andreotti G, Meyer TE, et al. Metabolic syndrome and insulin resistance in relation to biliary tract cancer and stone risks: A population-based study in Shanghai, China. Br J Cancer 2011;105:1424-9
38. Ata N, Kucukazman M, Yavuz B, et al. The metabolic syndrome is associated with complicated gallstone disease. Can J Gastroenterol 2011;25:274-6
39. Weikert C, Weikert S, Schulze MB, et al. Presence of gallstones or kidney stones and risk of type 2 diabetes. Am J Epidemiol 2010;171:447-54
40. Kim JM, Lee HL, Moon W, et al. [Association between insulin, insulin resistance, and gallstone disease in Korean general population]. Korean J Gastroenterol 2007;50:183-7
41. Nervi F, Miquel JF, Alvarez M, et al. Gallbladder disease is associated with insulin resistance in a high risk Hispanic population. J Hepatol 2006;45:299-305. (Pubitemid 44026566
42. Chang Y, Sung E, Ryu S, Park YW, Jang YM, Park M. Insulin resistance is associated with gallstones even in nonobese, non-Diabetic Korean men. J Korean Med Sci 2008;23: 644-50
43. Nakeeb A, Comuzzie AG, Al-Azzawi H, Sonnenberg GE, Kissebah AH, Pitt HA. Insulin resistance causes human gallbladder dysmotility. J Gastrointest Surg 2006;10:940-8
44. Biddinger SB, Haas JT, Yu BB, et al. Hepatic insulin resistance directly promotes formation of cholesterol gallstones. Nat Med 2008;14:778-82
45. Smelt AH. Triglycerides and gallstone formation. Clin Chim Acta 2010;411:1625-31
46. Bodmer M, Brauchli YB, Krahenbuhl S, Jick SS, Meier CR. Statin use and risk of gallstone disease followed by cholecystectomy. JAMA 2009;302:2001-7
47. Ahmed MH, Byrne CD. Potential therapeutic uses for ezetimibe beyond lowering LDL-c to decrease cardiovascular events. Diabetes Obes Metab 2010;12:958-66
48. Heaton KW. Cholesterol-rich gallstones. Mol Aspects Med 1987;9:89-96. (Pubitemid 17222707
49. Heaton KW. Review article: Epidemiology of gall-bladder disease-role of intestinal transit. Aliment Pharmacol Ther 2000;14:9-13. (Pubitemid 30349073
50. Ahmed MH, Osman MM, Alokail MS. Statins and breast cancer: A smoking gun or guilt by association?. Expert Opin Drug Saf 2006;5:599-601
51. Brenneman DE, Connor WE, Forker EL, DenBesten L. The formation of abnormal bile and cholesterol gallstones from dietary cholesterol in the prairie dog. J Clin Invest 1972;51: 1495-503
52. Holzbach RT. Animal models of cholesterol gallstone disease. Hepatology 1984;4:191S-8S.
53. Abedin MZ, Narins SC, Park EH, Smith P.R, Kirkwood KS. Lovastatin alters biliary lipid composition and dissolves gallstones: A long-Term study in prairie dogs. Dig Dis Sci 2002; 47:2192-210
54. Saunders KD, Cates JA, Abedin MZ, et al. Lovastatin inhibits gallstone formation in the cholesterol-fed prairie dog. Ann Surg 1991;214:149-54
55. Erichsen R, Froslev T, Lash TL, Pedersen L, Sorensen HT. Long-Term statin use and the risk of gallstone disease: A-population-based case-control study. Am J Epidemiol 2011; 173:162-70
56. Merzon E, Weiss NS, Lustman AJ, Elhayani A, Dresner J, Vinker S. Statin administration and risk of cholecystectomy: A population-based case-control study. Expert Opin Drug Saf 2010;9:539-43
57. Caroli-Bosc FX, Le GP, Pugliese P, et al. Role of fibrates and HMG-CoA reductase inhibitors in gallstone formation: Epidemiological study in an unselected population. Dig Dis Sci 2001;46:540-4
58. Tazuma S, Kajiyama G, Mizuno T, et al. A combination therapy with simvastatin and ursodeoxycholic acid is more effective for cholesterol gallstone dissolution than is ursodeoxycholic acid monotherapy. J Clin Gastroenterol 1998; 26:287-91
59. Hillebrant CG, Nyberg B, Gustafsson U, et al. Effects of combined treatment with pravastatin and ursodeoxycholic acid on hepatic cholesterol metabolism. Eur J Clin Invest 2002;32:528-34. (Pubitemid 36223423
60. Wang HH, Portincasa P, Mendez-Sanchez N, Uribe M, Wang DQ. Effect of ezetimibe on the prevention and dissolution of cholesterol gallstones. Gastroenterology 2008;134: 2101-10. (Pubitemid 351790745
61. Jonkers IJ, Smelt AH, Ledeboer M, et al. Gall bladder dysmotility: A risk factor for gall stone formation in hypertriglyceridaemia and reversal on triglyceride lowering therapy by bezafibrate and fish oil. Gut 2003;52:109-15. (Pubitemid 36020775